webinar register page

Tryp Therapeutics Q3 Investor Day
Please join us as we host our Quarterly Investor Day. The event will include a presentation by Tryp’s management team to discuss updates on its Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program as well as upcoming milestones for 2021 and beyond. The presentation will be followed with a Q&A session including Greg McKee, Chairman and Chief Executive Officer; Luke Hayes, Chief Financial Officer; and Jim Gilligan, Ph.D., President and Chief Science Officer.

Jul 29, 2021 09:00 AM in Pacific Time (US and Canada)

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) program i
Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Fraser Macdougall.